Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome

作者：Savira, Feby; Cao, Longxing; Wang, Ian; Yang, Wendi; Huang, Kevin; Hua, Yue; Jucker, Beat M.; Willette, Robert N.; Huang, Li; Krum, Henry; Li, Zhiliang; Fu, Tang; Wang, Bing Hui^*

来源：PLos One, 2017, 12(11): e0187459.

DOI：10.1371/journal.pone.0187459

• ORGANIC ANION TRANSPORTERS
• P-CRESYL SULFATE
• NF-KAPPA-B
• INDOXYL SULFATE
• GROWTH-FACTOR
• CARDIOVASCULAR-DISEASE
• ANGIOTENSIN RECEPTOR
• PROTEIN
• EXPRESSION
• INDUCTION

Intracellular accumulation of protein-bound uremic toxins in the setting of cardiorenal syndrome leads to adverse effects on cardiorenal cellular functions, where cardiac hypertrophy and cardiorenal fibrosis are the hallmarks. In this study, we sought to determine if Apoptosis Signal-Regulated Kinase 1 (ASKI), an upstream regulator of cellular stress response, mediates cardiac hypertrophy and cardiorenal fibrosis induced by indoxyl sulfate (IS) and p-cresol sulfate (PCS) in vitro, and whether ASK1 inhibition is beneficial to ameliorate these cellular effects. PCS augmented cardiac myocyte hypertrophy and fibroblast collagen synthesis (as determined by H-3-leucine and H-3-proline incorporation, respectively), similar to our previous finding with IS. IS and PCS also increased collagen synthesis of proximal tubular cells and renal mesangial cells. Pro-hypertrophic (alpha-skeletal muscle actin and beta-MHC) and pro-fibrotic genes (TGF-beta 1 and ctg) were induced by both IS and PCS. Western blot analyses revealed the activation of ASKI and downstream mitogen activated protein kinases (MAPKs) (p38MAPK and ERK1/2) as well as nuclear factor-kappa B (NF-kappa B) by IS and PCS. ASKI, OAT1/3, ERK1/2 and p38MAPK inhibitors suppressed all these effects. In summary, IS and PCS exhibit pro-hypertrophic and pro-fibrotic properties, at least in part, via the activation of ASKI and its downstream pathways. ASK1 inhibitor is an effective therapeutic agent to alleviate protein-bound uremic toxin-induced cardiac hypertrophy and cardiorenal fibrosis in vitro, and may be translated further for cardiorenal syndrome therapy.

• 出版日期2017-11-6
• 单位南方医科大学